Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, Viyash Scientific has informed that, Alivira Animal Health Limited, Ireland, step-down wholly owned subsidiary of the Company, has entered into a binding agreement today i.e. June 8, 2026, for the acquisition of 100% shareholding of BioForLife Italia s.r.l., Milan, Italy. The aggregate consideration for the transaction is EUR 16.975 million, structured as follows: a. EUR 15.0 million payable at closing; and b. EUR 1.975 million as deferred consideration, in accordance with the terms of the transaction documents. The transaction is subject to fulfilment of the applicable conditions precedent and receipt of such statutory and regulatory approvals as are applicable to the transaction. The details required under Regulation 30 of the SEBI Listing Regulations read with the applicable SEBI circulars are enclosed as Annexure I.
The above information is a part of company’s filings submitted to BSE.
